Journal
EXPERIMENTAL NEUROLOGY
Volume 270, Issue -, Pages 66-71Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.expneurol.2015.01.011
Keywords
Cell based assay; Acetylcholine receptor; MuSK; LRP4; Agrin; ColQ; Seronegative MG; Neuronal surface antibodies
Categories
Funding
- National Health Service (NHS) National Specialised Commissioning Group for Congenital Myasthenia (PMRC)
- Watney/MGA/NIHR fellowship [HMRVGX0]
- NIHR Oxford Biomedical Research Centre
Ask authors/readers for more resources
The increasing demand on diagnostic assays that are sensitive and specific for pathogenic antibodies, and the interest in identifying new antigens, prompted the development of cell-based assays for the detection of autoantibodies in myasthenia gravis and other autoimmune disorders. Cell-based assays were initially used to show that clustering the AChR improved the positivity in myasthenia gravis, and similar assays have now been applied to detection of antibodies to neuromuscular junction candidate proteins such as LRP4 and agrin. In addition cellbased assays have been used in the routine detection of antibodies to proteins expressed on the surface of neurons (NMDAR, LGI1, CASPR2, AMPAR, GABA-A/B, GlyR, and DPPX) and glia (AQP4, MOG). Here, we summarize the findings in myasthenia and discuss the advantages, disadvantages and controversial issues of using cellbased assays in the detection of these antibodies, and their relevance to the testing of preclinical models of disease. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available